Compare Nerdwallet Inc (NRDS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Recursion Pharmaceuticals Inc — how do they compare? Nerdwallet Inc trades at $9.22 (market cap $603.70M), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.5× Nerdwallet Inc's market cap, and Nerdwallet Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| NRDS | RXRX | |
|---|---|---|
Market Cap | $603.70M | $1.53B |
Sector | Financials | Health |
52-Week High | $15.93 | $6.79 |
52-Week Low | $7.58 | $2.84 |
Enterprise Value | $518.00M | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRDS trades at $9.12, down 1.51% today, with a bearish technical signal but strong fundamentals including a 93% gross margin and consistent earnings beats. Revenue grew to $836.6M in 2025, with net income reaching $48.7M. Positive analyst sentiment includes a $12.75 consensus target, though technical indicators show near-term pressure.
The stock offers value with a P/E of 9.87 and upside potential from analyst targets, but faces risks from competitive pressures and reliance on consumer financial health. Earnings growth and margin expansion are key catalysts, yet macroeconomic sensitivity could impact performance.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
